<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738019</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HAOS007</org_study_id>
    <nct_id>NCT04738019</nct_id>
  </id_info>
  <brief_title>A Multicenter, Prospective Observational Study to Evaluate the Incidence of Delayed-onset Nodules of YVOIRE Y-Solution 360, YVOIRE Y-Solution 540 or YVOIRE Y-Solution 720 Injected Into the Facial Skin Layer.</brief_title>
  <official_title>A Multicenter, Prospective Observational Study to Evaluate the Incidence of Delayed-onset Nodules of YVOIRE Y-Solution 360, YVOIRE Y-Solution 540 or YVOIRE Y-Solution 720 Injected Into the Facial Skin Layer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to evaluate the incidence of delayed-onset nodules of YVOIRE&#xD;
      Y-Solution 360, YVOIRE Y-Solution 540 or YVOIRE Y-Solution 720 injected into the facial skin&#xD;
      layer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Delayed-onset nodule.</measure>
    <time_frame>1 year.</time_frame>
    <description>Incidence of delayed-onset nodule in the facial area Y-Solution 360 or 540 or 720 is injected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Other adverse events.</measure>
    <time_frame>1 year.</time_frame>
    <description>Other adverse events occur in the facial area Y-Solution 360 or 540 or 720 is injected.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Healthy Condition</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Medical examination or treatment.</intervention_name>
    <description>Medical examination or treatment when delayed on-set nodule or other side effects occur due to Y-Solution filler injection.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any healthy male and female whose filler injection on facial area is already planned for&#xD;
        volume enhancement and anti-wrinkle treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planned for YVOIRE Y-Solution 360 or 540 or 720 filler injection in facial area&#xD;
             (except middle of the forehead, lips) for the volume enhancement or anti-wrinkle&#xD;
             treatment.&#xD;
&#xD;
          -  Male and female of 19 years or above age.&#xD;
&#xD;
          -  Informed consent to participate in the study.&#xD;
&#xD;
          -  Able to participate throughout the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prohibited in the Product Label.&#xD;
&#xD;
          -  Have active or infectious skin disease in injection area.&#xD;
&#xD;
          -  Autoimmune disease or HIV infected patient.&#xD;
&#xD;
          -  Received immunosuppressive therapy within 2 weeks.&#xD;
&#xD;
          -  Previously experienced Delayed-onset nodule after filler injection in facial area.&#xD;
&#xD;
          -  Previously experienced Hypertrophic scar or Keloid.&#xD;
&#xD;
          -  Have participated in an interventional clinical investigation within 30 days or plan&#xD;
             to participate one during the study period.&#xD;
&#xD;
          -  Ineligible for this clinical investigation as per Investigator's discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dong Yeop Shin</last_name>
    <phone>+82-2-6987-4147</phone>
    <email>dongyeopshin@lgchem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dong Yeop Shin</name>
      <address>
        <city>Seoul</city>
        <state>Gangseo-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Yeop Shin</last_name>
      <phone>+82-2-6987-4147</phone>
      <email>dongyeopshin@lgchem.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incidence rate of delayed-onset nodule or other side effects when YVOIRE Y-Solution 360 or 540 or 720 are used.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data is expected to be available during 2022.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

